X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Jim C. Stansel

Jim C. Stansel James C. Stansel is Executive Vice President, General Counsel and Corporate Secretary of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he is responsible for leading a team of lawyers in supporting PhRMA’s policy, advocacy and science priorities and in the development of sound legal policies impacting the pharmaceutical industry.

Recent Posts

Pass-through rebates do not violate non-interference clause but they do increase savings for seniors

By Jim C. Stansel  |    July 2, 2018
For more than a decade, Medicare Part D has successfully provided seniors with comprehensive prescription drug coverage. Key to its success is a unique, market-based structure of private-sector...   Read More

Long-awaited FDA guidance addresses one key obstacle to value-based contracting

By Jim C. Stansel  |    June 19, 2018
As part of the broader shift away from paying for volume to paying for value in health care, payors are increasingly pursuing value-based or results-based contracts with biopharmaceutical...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates